BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 17950795)

  • 21. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
    Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia.
    Wongwiwatthananukit S; Sansanayudh N; Dhummauppakorn R; Kitiyadisai C
    Ann Pharmacother; 2006 Nov; 40(11):1917-23. PubMed ID: 17003082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
    Lloret R; Ycas J; Stein M; Haffner S;
    Am J Cardiol; 2006 Sep; 98(6):768-73. PubMed ID: 16950182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
    Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
    Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
    Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rosuvastatin in the management of hyperlipidemia.
    Cheng JW
    Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
    Hirsch M; O'donnell J; Olsson A
    Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia.
    Kawashiri MA; Nohara A; Noguchi T; Tada H; Nakanishi C; Mori M; Konno T; Hayashi K; Fujino N; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Am J Cardiol; 2012 Feb; 109(3):364-9. PubMed ID: 22112743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study).
    Milionis HJ; Rizos E; Kostapanos M; Filippatos TD; Gazi IF; Ganotakis ES; Goudevenos J; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2006 Jun; 22(6):1123-31. PubMed ID: 16846545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
    Asztalos BF; Le Maulf F; Dallal GE; Stein E; Jones PH; Horvath KV; McTaggart F; Schaefer EJ
    Am J Cardiol; 2007 Mar; 99(5):681-5. PubMed ID: 17317371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis.
    Middleton A; Binbrek AS; Fonseca FA; Wilpshaar W; Watkins C; Strandberg TE
    Curr Med Res Opin; 2006 Jun; 22(6):1181-91. PubMed ID: 16846551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of efficacy of rosuvastatin 5 mg.
    Teramoto T; Watkins C
    Int J Clin Pract; 2005 Jan; 59(1):92-101. PubMed ID: 15707472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
    Betteridge DJ; Gibson JM; Sager PT
    Am J Cardiol; 2007 Oct; 100(8):1245-8. PubMed ID: 17920365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.